SCHEMBL490985

SCHEMBL490985

CC1(c2c(-c3ccc(Cl)cc3)[nH]c3nccnc23)CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 18/20 0.57
GSK3B P49841 18/20 0.57
CCNB2 O95067 17/20 0.57
CCNB1 P14635 17/20 0.57
CCNB3 Q8WWL7 17/20 0.57
GSK3A P49840 16/20 0.57
CDK5 Q00535 11/20 0.57
CDK5R1 Q15078 10/20 0.57
AURKA O14965 2/20 0.36
MAP4K4 O95819 2/20 0.36
PAK4 O96013 2/20 0.36
ABL1 P00519 2/20 0.36
FYN P06241 2/20 0.36
RET P07949 2/20 0.36
KDR P35968 2/20 0.36
MAPK8 P45983 2/20 0.36
CDK8 P49336 2/20 0.36
ACVR1 Q04771 2/20 0.36
PTK2 Q05397 2/20 0.36
LRRK2 Q5S007 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491139 0.85 CCNB2 (0.59) CDK1GSK3BCCNB2CCNB1CCNB3
Bromide SCHEMBL490385 0.79 GSK3A (0.59) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL490088 0.78 CCNB2 (0.63) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL490581 0.73 CDK1 (1.00) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL490956 0.70 CDK1 (1.00) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL31069480 0.70 CDK1 (1.00) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL490878 0.66 GSK3A (1.00) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL490764 0.63 GSK3A (1.00) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL10014914 0.62 CCNB2 (1.00) CDK1GSK3BCCNB2CCNB1CCNB3
SCHEMBL12596028 0.61 SLC6A4 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106050-B2 6-[1-(4-Chlorophenyl)-1-cyclopropyl][5H]pyrrolo[2,3-b]pyrazine; cyclin-dependent kinases and glycogen synthase kinase-3 inhibitor; antiproliferative, anticarcinogenic agent; neurodegenerative disorders; controlling the cell cycle apoptosis, neuronal functions, transcription and exocytosis CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-01-31 US disclosed
US-20080161312-A1 Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2008-07-03 US disclosed
EP-1388541-A1 Pyrrolopyrazines as kinase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2004-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161312-A1 Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications CDK2, PLK2, CDK5 CDK1 39/4885GSK3B 599/4885CCNB2 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.